Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes
CompletedNot applicableNCT04433975
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this research study is to look at the effect of programs aimed at helping people manage chronic pain and medication treatment. The program sessions focus on educational information and strategies for pain and medication management. The researchers enroll people who have chronic pain and have recently begun buprenorphine treatment to see if participants could benefit from these programs. This research study will help the researchers learn how to improve current therapies for pain and medication management.
Study details
- Official title
- Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes: A Randomized Controlled Trial
- Conditions
- Opioid-use Disorder
- Medication Assisted Treatment
- Chronic Pain
- Interventions
- Behavioral: Psychosocial Pain Management (PPMI)
- Behavioral: Enhanced Usual Care (EUC)
- Sponsor
- University of Michigan
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH); US Department of Veterans Affairs
- Start date
- 2020-08-14
- Primary completion
- 2024-05-23
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * having a diagnosis of an opioid use disorders (OUD) within the past 12 months; * started buprenorphine (the term we use to refer to all buprenorphine products including buprenorphine/naloxone) treatment within the past 6 months * at least moderate or greater self-reported pain on average over the past 3 months; * regular and consistent access to a telephone and willingness to use the phone for study sessions. Exclusion Criteria: * buprenorphine medication prescribed in the form of a monthly injection and/or a transdermal patch * self-reported pregnancy at the time of study enrollment * currently living outside of the United States
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04433975